{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:12:10Z","timestamp":1790957530445,"version":"4.1.0"},"reference-count":54,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.dsx.2023.102804","type":"journal-article","created":{"date-parts":[[2023,6,2]],"date-time":"2023-06-02T23:47:32Z","timestamp":1685749652000},"page":"102804","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus"],"prefix":"10.1016","volume":"17","author":[{"given":"Jingyi","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriette GC.","family":"Van Spall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Likang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Shahzeb","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambarish","family":"Pandey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lehana","family":"Thabane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuerui","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaoyao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory YH.","family":"Lip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1184-1791","authenticated-orcid":false,"given":"Guowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.dsx.2023.102804_bib1","series-title":"DIABETES ATLAS","year":"2019"},{"issue":"2","key":"10.1016\/j.dsx.2023.102804_bib2","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3390\/metabo12020183","article-title":"Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. Other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies","volume":"12","author":"Caruso","year":"2022","journal-title":"Metabolites"},{"issue":"12","key":"10.1016\/j.dsx.2023.102804_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamahealthforum.2021.4182","article-title":"Racial, ethnic, and socioeconomic inequities in glucagon-like peptide-1 receptor agonist use among patients with diabetes in the US","volume":"2","author":"Eberly","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"1","key":"10.1016\/j.dsx.2023.102804_bib4","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1186\/s12933-021-01430-3","article-title":"SGLT-2 inhibitors and cardiorenal outcomes in patients with or without type 2 diabetes: a meta-analysis of 11 CVOTs","volume":"20","author":"Giugliano","year":"2021","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"10.1016\/j.dsx.2023.102804_bib5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12933-022-01474-z","article-title":"The effect of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors on cardiorenal outcomes: a network meta-analysis of 23 CVOTs","volume":"21","author":"Giugliano","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 1","key":"10.1016\/j.dsx.2023.102804_bib6","first-page":"S90","article-title":"9. Pharmacologic approaches to glycemic treatment: standards of medical care in diabetes-2019","volume":"42","year":"2019","journal-title":"Diabetes Care"},{"issue":"2","key":"10.1016\/j.dsx.2023.102804_bib7","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/eurheartj\/ehz486","article-title":"2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD","volume":"41","author":"Cosentino","year":"2020","journal-title":"Eur Heart J"},{"key":"10.1016\/j.dsx.2023.102804_bib9","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2337\/db16-0806","article-title":"Differentiation of diabetes by pathophysiology, natural history, and prognosis","volume":"66","author":"Skyler","year":"2017","journal-title":"Diabetes"},{"key":"10.1016\/j.dsx.2023.102804_bib10","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1007\/s11892-013-0421-9","article-title":"Race\/ethnic difference in diabetes and diabetic complications","volume":"13","author":"Spanakis","year":"2013","journal-title":"Curr Diabetes Rep"},{"issue":"1","key":"10.1016\/j.dsx.2023.102804_bib11","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1749-6632.2012.06838.x","article-title":"Type 2 diabetes in South Asians: similarities and differences with white Caucasian and other populations","volume":"1281","author":"Gujral","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"1","key":"10.1016\/j.dsx.2023.102804_bib12","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/nyas.12098","article-title":"Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States","volume":"1281","author":"Ma","year":"2013","journal-title":"Ann N Y Acad Sci"},{"issue":"9","key":"10.1016\/j.dsx.2023.102804_bib13","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00125-022-05736-z","article-title":"Exploring ethnic representativeness in diabetes clinical trial enrolment from 2000 to 2020: a chronological survey","volume":"65","author":"Li","year":"2022","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.dsx.2023.102804_bib14","doi-asserted-by":"crossref","first-page":"e116","DOI":"10.2337\/dc22-0261","article-title":"Enrollment of Black, indigenous, and other people of color in multicountry randomized controlled trials of diabetes conducted in north America and europe","volume":"45","author":"Zhang","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2023.102804_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101697","article-title":"Age, sex, race, BMI, and duration of diabetes differences in cardiovascular outcomes with glucose lowering drugs in type 2 diabetes: a systematic review and meta-analysis","volume":"54","author":"Diallo","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.dsx.2023.102804_bib16","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.2337\/dc19-2419","article-title":"Efficacy of modern diabetes treatments DPP-4i, SGLT-2i, and GLP-1RA in white and asian patients with diabetes: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Gan","year":"2020","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.dsx.2023.102804_bib17","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.2337\/dc20-3007","article-title":"Meta-analyses of results from randomized outcome trials comparing cardiovascular effects of SGLT2is and GLP-1RAs in asian versus white patients with and without type 2 diabetes","volume":"44","author":"Lee","year":"2021","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/j.dsx.2023.102804_bib18","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.2337\/dc21-1722","article-title":"Comparable cardiorenal benefits of SGLT2 inhibitors and GLP-1RAs in asian and white populations: an updated meta-analysis of results from randomized outcome trials","volume":"45","author":"Tang","year":"2022","journal-title":"Diabetes Care"},{"key":"10.1016\/j.dsx.2023.102804_bib19","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting Items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"issue":"4","key":"10.1016\/j.dsx.2023.102804_bib20","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1056\/NEJMoa1812389","article-title":"DECLARE\u2013TIMI 58 investigators. Dapagliflozin and cardiovascular outcomes in type 2 diabetes","volume":"380","author":"Wiviott","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.dsx.2023.102804_bib21","first-page":"S343","article-title":"Single-dose colesevelam has no effect on postprandial GLP-1 levels, but increases CCK levels and decreases gallbladder refilling and gastric emptying in type 2 diabetes","volume":"58","author":"Bahne","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.dsx.2023.102804_bib22","series-title":"Cochrane Handbook for systematic reviews of interventions version 5.1.0","author":"Higgins","year":"2011"},{"issue":"6","key":"10.1016\/j.dsx.2023.102804_bib23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.dsx.2023.102804_bib24","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1002\/jrsm.1402","article-title":"The median and the mode as robust meta-analysis estimators in the presence of small-study effects and outliers","volume":"11","author":"Hartwig","year":"2020","journal-title":"Res Synth Methods"},{"issue":"23","key":"10.1016\/j.dsx.2023.102804_bib25","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"ELIXA investigators. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"10157","key":"10.1016\/j.dsx.2023.102804_bib26","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Harmony Outcomes committees and investigators. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.dsx.2023.102804_bib27","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa2030186","article-title":"SCORED investigators. Sotagliflozin in patients with diabetes and chronic kidney disease","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.dsx.2023.102804_bib28","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"SOLOIST-WHF trial investigators. Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2023.102804_bib29","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","article-title":"GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables","volume":"64","author":"Guyatt","year":"2011","journal-title":"J\u00a0Clin Epidemiol"},{"issue":"10193","key":"10.1016\/j.dsx.2023.102804_bib30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"REWIND Investigators. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.dsx.2023.102804_bib31","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"AMPLITUDE-O trial investigators. Cardiovascular and renal outcomes with Efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.dsx.2023.102804_bib32","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"EXSCEL study group. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.dsx.2023.102804_bib33","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1056\/NEJMoa1901118","article-title":"PIONEER 6 investigators. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"381","author":"Husain","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.dsx.2023.102804_bib34","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"SUSTAIN-6 investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.dsx.2023.102804_bib35","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"LEADER steering committee; LEADER trial investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N\u00a0Engl J Med"},{"issue":"22","key":"10.1016\/j.dsx.2023.102804_bib36","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1504720","article-title":"EMPA-REG OUTCOME investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes","volume":"373","author":"Zinman","year":"2015","journal-title":"N\u00a0Engl J Med"},{"issue":"19","key":"10.1016\/j.dsx.2023.102804_bib37","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1093\/eurheartj\/ehv728","article-title":"EMPA-REG OUTCOME\u00ae trial investigators. Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME\u00ae trial","volume":"37","author":"Fitchett","year":"2016","journal-title":"Eur Heart J"},{"issue":"2","key":"10.1016\/j.dsx.2023.102804_bib38","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1253\/circj.CJ-16-1148","article-title":"EMPA-REG OUTCOME\u00ae investigators. Empagliflozin and cardiovascular outcomes in asian patients with type 2 diabetes and established cardiovascular disease- results from EMPA-REG OUTCOME","volume":"81","author":"Kaku","year":"2017","journal-title":"Circ J"},{"issue":"5","key":"10.1016\/j.dsx.2023.102804_bib39","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1161\/STROKEAHA.116.015756","article-title":"EMPA-REG OUTCOME investigators (empagliflozin cardiovascular outcome event trial in type 2 diabetes mellitus patients). Empagliflozin and cerebrovascular events in patients with type 2 diabetes mellitus at high cardiovascular risk","volume":"48","author":"Zinman","year":"2017","journal-title":"Stroke"},{"issue":"3","key":"10.1016\/j.dsx.2023.102804_bib40","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/jdi.12971","article-title":"Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME\u00ae trial","volume":"10","author":"Kadowaki","year":"2019","journal-title":"J\u00a0Diabetes Investig"},{"issue":"4","key":"10.1016\/j.dsx.2023.102804_bib41","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/dom.14626","article-title":"The effect of empagliflozin on the total burden of cardiovascular and hospitalization events in the Asian and non-Asian populations of the EMPA-REG OUTCOME trial of patients with type 2 diabetes and cardiovascular disease","volume":"24","author":"Kaku","year":"2022","journal-title":"Diabetes Obes Metabol"},{"issue":"7","key":"10.1016\/j.dsx.2023.102804_bib42","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1056\/NEJMoa1611925","article-title":"CANVAS Program collaborative group. Canagliflozin and cardiovascular and renal events in type 2 diabetes","volume":"377","author":"Neal","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.dsx.2023.102804_bib43","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/S2213-8587(18)30141-4","article-title":"Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials","volume":"6","author":"Perkovic","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"10.1016\/j.dsx.2023.102804_bib44","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1161\/STROKEAHA.118.023009","article-title":"Canagliflozin and stroke in type 2 diabetes mellitus","volume":"50","author":"Zhou","year":"2019","journal-title":"Stroke"},{"issue":"24","key":"10.1016\/j.dsx.2023.102804_bib45","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"CREDENCE trial investigators. Canagliflozin and renal outcomes in type 2 diabetes and Nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"9","key":"10.1016\/j.dsx.2023.102804_bib46","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1161\/CIRCULATIONAHA.119.042007","article-title":"Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups","volume":"140","author":"Mahaffey","year":"2019","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.dsx.2023.102804_bib47","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/S2213-8587(19)30180-9","article-title":"Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"15","key":"10.1016\/j.dsx.2023.102804_bib48","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa2004967","article-title":"VERTIS CV investigators. Cardiovascular outcomes with Ertugliflozin in type 2 diabetes","volume":"383","author":"Cannon","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.dsx.2023.102804_bib49","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.dsx.2023.102804_bib50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ahj.2015.12.009","article-title":"Rationale and design of the EXenatide Study of cardiovascular event lowering (EXSCEL) trial","volume":"174","author":"Holman","year":"2016","journal-title":"Am Heart J"},{"key":"10.1016\/j.dsx.2023.102804_bib51","series-title":"Racial and ethnic subgroup reporting in diabetes randomized controlled trials published from 2000 to 2020: a survey","author":"Li","year":"2022"},{"key":"10.1016\/j.dsx.2023.102804_bib52","doi-asserted-by":"crossref","first-page":"n1091","DOI":"10.1136\/bmj.n1091","article-title":"SGLT-2 inhibitors or GLP-1 receptor agonists for adults with type 2 diabetes: a clinical practice guideline","volume":"373","author":"Li","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.dsx.2023.102804_bib53","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1001\/jama.2022.13885","article-title":"Association of race and ethnicity with prescription of SGLT2 inhibitors and GLP1 receptor agonists among patients with type 2 diabetes in the veterans health administration system","volume":"328","author":"Lamprea-Montealegre","year":"2022","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.dsx.2023.102804_bib54","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13145","article-title":"Understanding of interaction (subgroup) analysis in clinical trials","volume":"49","author":"Brankovic","year":"2019","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.dsx.2023.102804_bib55","first-page":"162","article-title":"Subgroup analysis and interaction tests: why they are important and how to avoid common mistakes","volume":"43","author":"Ferreira","year":"2017","journal-title":"J\u00a0Bras Pneumol"}],"container-title":["Diabetes & Metabolic Syndrome: Clinical Research & Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123001005?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1871402123001005?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T09:23:52Z","timestamp":1761729832000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1871402123001005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":54,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["S1871402123001005"],"URL":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102804","relation":{},"ISSN":["1871-4021"],"issn-type":[{"value":"1871-4021","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors on cardiovascular and kidney outcomes in Asian versus White patients with type 2 diabetes mellitus","name":"articletitle","label":"Article Title"},{"value":"Diabetes & Metabolic Syndrome: Clinical Research & Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dsx.2023.102804","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Research Trust of DiabetesIndia (DiabetesIndia) and National Diabetes Obesity and Cholesterol Foundation (N-DOC). Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102804"}}